Poly Medicure Limited releases its financial performance for Q1 2026, covering the period ending June 30. The report outlines earnings and operational updates for the quarter. Investors and stakeholders await details on revenue, profitability, and key business developments.
Poly Medicure reports a **29% year-over-year decline in net profit** to **Rs 65.04 crore** in Q4 FY26, despite a **21.25% revenue increase** to **Rs 534.51 crore**. The company’s consolidated net profit fell sharply while revenue growth failed to offset rising costs or other pressures. Shares close **3.78% lower** at **Rs 1,538.35** following the earnings update.
Poly Medicure is acquiring the Netherlands-based PendraCare Group for **₹188.5 crore**, with the remaining **10% stake** set to be purchased in **2030** based on PendraCare’s **2029 EBITDA performance**. The deal follows a structured payment plan tied to financial milestones.
Poly Medicure is investing ₹500 crore to build three new manufacturing facilities specializing in renal, cardiology, and oncology medical devices. The company targets expansion into the US, Brazil, and Europe, leveraging FDA-approved products to strengthen its global market presence by FY26.
